Who
Matthew Strobeck
Director
Company insider
Files Form 4 as: Director, QuidelOrtho; Director, Biodesix; Director, Accelerate Diagnostics; 10% owner, Elutia; Director, Quidel Corp /de/; Director, Metabolix; Director, Santarus.
In numbers
- Trades disclosed
- 258
- Buys
- 28
- Sells
- 2
- Bought
- $13.7M
- Sold
- $852K
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 9 Nov 2006
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | QDEL QuidelOrthoDiagnostics & Labs | SEC FORM 4 Code A | —6,829 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | QDEL QuidelOrthooption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —6,829 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | QDEL QuidelOrthooption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —6,829 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | QDEL QuidelOrthoDiagnostics & Labs | SEC FORM 4 Code A | —6,829 at $0.00 | filing |
| 13 Feb 2026filed 13 Feb 2026 | QDEL QuidelOrthoDiagnostics & Labs | SEC FORM 4 Bought | $240K10,000 at $23.96 | filing |
| 13 Feb 2026filed 13 Feb 2026 | QDEL QuidelOrthoDiagnostics & Labs | SEC FORM 4 Bought | $240K10,000 at $23.96 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,804 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,804 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | QDEL QuidelOrthooption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,829 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | QDEL QuidelOrthooption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,929 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | QDEL QuidelOrthoDiagnostics & Labs | SEC FORM 4 Code A | —4,929 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —80,525 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —42,010 at $0.00 | filing |
| 5 Nov 2024filed 6 Nov 2024 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Bought | $5,6004,000 at $1.40 | filing |
| 5 Nov 2024filed 6 Nov 2024 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Bought | $50K36,000 at $1.40 | filing |
| 24 May 2024filed 29 May 2024 | QDEL QuidelOrthooption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —2,416 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | QDEL QuidelOrthoDiagnostics & Labs | SEC FORM 4 Code A | —2,416 at $0.00 | filing |
| 23 May 2024filed 23 May 2024 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —1,304 at $0.00 | filing |
News
QuidelOrtho (NASDAQ:QDEL) Shares Gap Down – What's Next?QDEL · tickerreport.com · 21 Oct 2026Financial Comparison: LivaNova (NASDAQ:LIVN) vs. QuidelOrtho (NASDAQ:QDEL)QDEL · themarketsdaily.com · 17 Oct 2026QuidelOrtho Grants Stock Units Covering 50,323 Shares to Two New HiresQDEL · econotimes.com · 16 Oct 2026
0 headlines in the last 90 days name Matthew Strobeck; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.